Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL) was written by Mayer, Nicole;Schweiger, Martina;Fuchs, Elisabeth;Migglautsch, Anna K.;Doler, Carina;Grabner, Gernot F.;Romauch, Matthias;Melcher, Michaela-Christina;Zechner, Rudolf;Zimmermann, Robert;Breinbauer, Rolf. And the article was included in Bioorganic & Medicinal Chemistry in 2020.SDS of cas: 89978-52-9 This article mentions the following:
High serum fatty acid (FA) levels are causally linked to the development of insulin resistance, which eventually progresses to type 2 diabetes and non-alc. fatty liver disease (NAFLD) generalized in the term metabolic syndrome. Adipose triglyceride lipase (ATGL) is the initial enzyme in the hydrolysis of intracellular triacylglycerol (TG) stores, liberating fatty acids that are released from adipocytes into the circulation. Hence, ATGL-specific inhibitors have the potential to lower circulating FA concentrations, and counteract the development of insulin resistance and NAFLD. In this article, we report about structure-activity relationship (SAR) studies of small mol. inhibitors of murine ATGL which led to the development of Atglistatin. Atglistatin is a specific inhibitor of murine ATGL, which has proven useful for the validation of ATGL as a potential drug target. In the experiment, the researchers used many compounds, for example, Ethyl 2-bromoisonicotinate (cas: 89978-52-9SDS of cas: 89978-52-9).
Ethyl 2-bromoisonicotinate (cas: 89978-52-9) belongs to pyridine derivatives. Pyridines are an important class of heterocycles and occur in polysubstituted forms in many naturally occurring biologically active compounds, drug molecules and chiral ligands. Pyridine derivatives are also useful as small-molecule 婵?helix mimetics that inhibit protein-protein interactions, as well as functionally selective GABA ligands.SDS of cas: 89978-52-9